HomeBioPharma

BioPharma

BioPharma

Solid says early data suggest ‘differentiated’ Duchenne gene therapy

-

BioPharma

Biogen buys rights to Stoke’s rare epilepsy drug

BioPharma

FTC sues major pharmacy benefit managers over insulin prices

BioPharma

AstraZeneca, Daiichi’s Enhertu successor faces more questions after latest stumble

BioPharma

Biogen, UCB get the lupus data they’ve waited two decades for

BioPharma

Pfizer exits Sangamo pact; Roche, Ideaya strike ADC deals

0

BioPharma

Lilly pads cancer drug pipeline with Scorpion deal

0

BioPharma

Orbis raises $93M to turn popular biologics into pills

0

BioPharma

IGM’s autoimmune pivot backfires as top drug disappoints in testing

0

BioPharma

JPM25: The FDA’s future, AbbVie’s second thoughts and Lilly’s lesson

0

BioPharma

Medicare will negotiate Novo’s GLP-1 drug price. Here’s what that means for Ozempic, Wegovy.

0

BioPharma

J&J joins Pfizer in detailing impact of Part D redesign

0

BioPharma

RFK Jr. signals he’ll back Trump abortion policies, despite prior stance

0

BioPharma

J&J oncology sales grow, but shares slide on outlook

0

BioPharma

Sara Brenner, FDA device official, named agency’s acting head

0

BioPharma

Flagship-backed Omega signals it’s headed toward bankruptcy

0

BioPharma

RFK Jr. secured support of key Republican with vaccine pledges

0

1 234 Page 3 of 4

Most Read

Solid says early data suggest ‘differentiated’ Duchenne gene therapy

Biogen buys rights to Stoke’s rare epilepsy drug

FTC sues major pharmacy benefit managers over insulin prices

Top 10 Companies in Biosimilars Production